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Background:  In  Canada,  private  purchase  of  human  papilloma  virus  (HPV)  vaccines  has  been  possible  since
2006.  In Alberta,  Canada,  a publicly  funded  quadrivalent  HPV  vaccine  program  began  in the  2008/2009
school  year.  There  have  been  concerns  about  adverse  events,  including  venous  thromboembolism  (VTE)
associated  with HPV  vaccines.  We  describe  the  frequencies  of adverse  events  following  HPV  vaccination
among  Alberta  females  aged  9 years  or older  and  look  at VTE  following  HPV  vaccination.
Methods:  We used  the  Alberta  Immunization  and  Adverse  Reaction  to Immunization  (Imm/ARI)  repository
(publicly  funded  vaccine),  the  population-based  Pharmaceutical  Information  Network  (PIN)  information
system  (dispensing  of  a vaccine),  and  the  Alberta  Morbidity  and  Ambulatory  Care  Abstract  reporting
system  (MACAR)  for June  1, 2006–November  19, 2014.  Deterministic  data  linkage  used  unique  personal
identiﬁers.  We  identiﬁed  all reported  adverse  events  following  immunization  (AEFI)  and  all  emergency
department  (ED)  utilization  or hospitalizations  within  42  days  of  immunization.  We  calculated  the  fre-
quency  of  AEFI  by  type,  rates  per 100,000  doses  of HPV  vaccine  administered  and  the  frequencies  of
ICD-10-CA  codes  for hospitalizations  and  emergency  department  visits.
Results: Over  the  period  195,270  females  received  528,913  doses  of HPV  vaccine.  Of  those  receiving  at least
one dose,  192  reported  one  or more  AEFI  events  (198  AEFI  events),  i.e.,  37.4/100,000  doses  administered
(95%  CI 32.5–43.0).  None  were  consistent  with  VTE.  Of  the women  who  received  HPV  vaccine  958 were
hospitalized  and  19,351  had  an  ED  visit  within  42  days  of  immunization.  Four  women  who had  an  ED
visit  and  hospitalization  event  were  diagnosed  with  VTE.  Three  of these  had  other  diagnoses  known  to
be associated  with  VTE;  the  fourth  woman  had  VTE  among  ED  diagnoses  but  not among  those  for  the
hospitalization.
Conclusions:  Rates  of  AEFI  after  HPV  immunization  in Alberta  are  low  and  consistent  with  types  of  events
seen elsewhere.
© 2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-NDAbbreviations: WHO, World Health Organization; HPV, human papillomavirus;
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Alberta) Morbidity and Ambulatory Care Abstract Reporting; ICD-10-CA, Interna-
ional Classiﬁcation of Diseases, 10th Revision-Canadian Adaptation.
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1. Introduction
The World Health Organization (WHO) recommends the human
papillomavirus (HPV) vaccine for prevention of cervical cancer
and other HPV-related diseases [1]. Quadrivalent HPV (qHPV) vac-
cine was  authorized and became available for private purchase in
Canada in 2006 for females aged 9–26 years. This authorization
was expanded to include females aged 9–45 years in 2011. Bivalent
HPV (bHPV) vaccine was also authorized for use among females
aged 10–25 years in 2010. Canada’s National Advisory Commit-
tee on Immunization (NACI) has recommended both vaccines in
females aged 9–26 years of age [2]. Both vaccines were initially
administered in a three-dose series; however NACI now recom-
mends a two-dose series for immunocompetent persons aged
9–14 years [2].
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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resulted in hospitalization and counted the number of ‘serious’X.C. Liu et al. / Vacc
In Alberta, the publicly funded routine childhood and adoles-
ent vaccines are administered exclusively by public health nurses.
lberta began to deliver a publicly funded three-dose qHPV vaccine
eries in the 2008/09 school year for females in grade 5, most of
hom were aged 10–11 years [3]. A catch-up program was imple-
ented from 2009/10 to 2011/12 for females in grade 9 (most of
hom were aged 14–15 years). Both qHPV and bHPV vaccines are
lso available for private purchase through pharmacies.
The monitoring of adverse events following immunization
AEFI) contributes to vaccine safety surveillance and is an important
omponent of all vaccination programs. Vaccine safety is monitored
y passive surveillance in Alberta. There have been community con-
erns that HPV vaccines may  be associated with adverse events.
enous thromboembolic events (VTE) are a particular concern, as
ome were reported to occur following HPV immunization in the
nited States [4]. The objective of this study is to describe the fre-
uencies of adverse events among females aged 9 years or older that
ccurred following HPV vaccination including looking speciﬁcally
t VTE following HPV vaccination.
. Methods
.1. Ethics and role of funding source
The study was approved by the University of Calgary Conjoint
ealth Research Ethics Board (Ethics ID: REB 14-0598). The funding
ource had no role in study design, collection, analysis or interpre-
ation of data, report writing or publication decision.
.2. Data source and data extraction
Alberta has a publicly funded universal healthcare system in
hich >99% of residents are registered [5]. The registration ﬁle for
his program includes a Person Health Number that serves as a
nique personal identiﬁer (ULI) [6] that permits data linkage at the
evel of the individual across other administrative databases. We
sed ULI to deterministically link data on vaccination, AEFI, and
ealthcare utilization.
Alberta’s Immunization and Adverse Reaction to Immuniza-
ion repository (Imm/ARI) contains complete vaccination records,
ncluding AEFI, for all publicly funded vaccines that were admin-
stered by public health since 2006. Vaccination records prior to
006 comprise historical data and are entered electronically into
mm/ARI by public health nurses after review of paper vaccination
ecords. The Pharmaceutical Information Network (PIN) contains
ecords of all prescriptions dispensed by pharmacies, whether pri-
ately or publicly funded. In the case of HPV vaccine, this would
nly include privately funded vaccines. It is estimated that PIN
aptures over 95% of dispensed pharmacologic products [7]. We
ave assumed that all vaccine dispensed according to PIN was actu-
lly administered to the purchaser as the cost to purchaser of HPV
accine is about $150/dose [8]. Both Imm/ARI and PIN contain infor-
ation on the patient, vaccine, dose, and date that vaccine was
dministered/dispensed [9].
In Alberta, AEFI surveillance is a passive reporting system. Indi-
iduals who experience an AEFI report to their vaccine provider,
ho completes a provincial AEFI reporting form; the data are
ntered into Imm/ARI [10]; Alberta Health then reports AEFI to
he Public Health Agency of Canada. The provincial AEFI reporting
orm consists of a close ended checklist of types of adverse events,
ccompanied by an open ended text ﬁeld into which a descrip-
ion of event is to be entered as well as an open ended comment
ection. The reporting form also collects time of onset following
mmunization, outcome, hospitalization dates, patient identiﬁers,
accine antigens, vaccination date, and dose number. Alberta (2016) 1800–1805 1801
policy is that providers should “Report events that do not meet
speciﬁc case deﬁnitions but are felt to be signiﬁcant (i.e., serious
or unusual) under [checkbox] Other Severe or Unusual Events. . .
When an AEFI is:
• Serious (death, hospitalization, congenital abnormality, residual
abnormality, life threatening), unexpected (in terms of type or
frequency),
• Of concern (to the vaccinee, his/her caregiver(s) or AEFI
reporter).”
AEFI’s that meet any of these criteria should be reported regard-
less of consistency with time period of occurrence for the event of
the case deﬁnition of any such event. VTE cases are captured by the
checkbox ‘other unusual events’ on the AEFI reporting form. Event
codes and text descriptions on all AEFI reports are reviewed by
trained nurses and coded into Imm/ARI. Information related to hos-
pitalizations and emergency department (ED) visits are captured
in the Alberta Morbidity and Ambulatory Care Abstract Reporting
(MACAR) system, including dates of admission and discharge, and
ICD-10-CA (International Classiﬁcation of Diseases, 10th Revision-
Canadian Adaptation) codes for diagnoses.
We extracted data on vaccinations, AEFI reports, hospitaliza-
tions and ED visits (within 42 days of vaccination) [4,11] for all
females for whom an HPV dispense or vaccination event was
recorded over June 1, 2006–November 19, 2014, using ULI to link
records for unique individuals.
2.3. Data analysis
We counted the number of females who received one or more
doses of HPV vaccine by number of doses received and age at
ﬁrst dose. We  described the frequencies of occurrence of AEFIs
by type of AEFI, and dose number associated with the AEFI. We
calculated rates of AEFI per 100,000 doses of HPV vaccine dis-
pensed/administered by dividing counts of AEFIs by the number of
vaccine doses received among the population of interest over the
period. We  described hospitalizations within 42 days of HPV vacci-
nations by ICD-10-CA diagnostic codes for the most responsible
diagnoses for all hospitalizations within 42 days of immuniza-
tion. “Most responsible diagnosis” is recorded by the health care
provider at discharge, using general coding standards that deﬁne
the most responsible diagnostic ICD code as that responsible for the
greatest portion of the length of stay or greatest use of resources
[12]. A hospitalization event is deﬁned as a hospital visit where a
person was  admitted and discharged from a hospital. Some hos-
pitalization events were recorded twice because the person had
one hospital visit that was temporally associated with receipt of
two different vaccine doses (e.g., was  hospitalized within 42 days
of receiving both dose 1 and dose 2). For these, we removed the
duplicate event and counted it as a single hospitalization event.
For each person, we assumed that a transfer from one hospi-
tal to another had occurred if the date of discharge from the
ﬁrst hospital was  the same as the date of admission to a sec-
ond hospital. We  counted each hospital transfer as a separate
event. However, for the purpose of describing the frequency of
the most responsible diagnoses (the diagnosis that contributed
the greatest to length of stay) for such persons, we  counted each
most responsible diagnosis if they differed between hospitaliza-
tion events. We  operationally deﬁned ‘serious’ AEFI as those thatAEFI. We  linked hospitalizations and ED visits to identify those
who reported both events within 42 days of vaccination. Data
analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary,
NC 2011).
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.4. AEFI review to identify VTE
One investigator (MLR), a physician, reviewed all text descrip-
ions for AEFIs coded as ‘other unusual events’ for evidence that the
EFI might have been VTE.
.5. Identiﬁcation of VTE not captured by AEFI reports
In order to maximize the chances of ﬁnding a VTE that was
ot captured by an AEFI report within Imm/ARI, we  identiﬁed
ithin MACAR all females who were hospitalized or visited the
D within 42 days of vaccination by deterministically linking
mm/ARI, PIN and MACAR using the ULI. Our deﬁnition of VTE for
his study was the occurrence of an ICD-10-CA diagnostic code
f I80.x or I82.x in any of the potential diagnostic code ﬁelds
25) for a hospitalization or ED (10) visit. For any woman  who
ad such an ICD-10-CA code for a hospitalization or ED visit,
ne investigator (MLR) reviewed all ICD codes for that event
o assess if they were consistent with any other condition for
hich VTE is known to occur as per Spencer and colleagues
13].
. Results
.1. Source population
As can be seen from Table 1, from June 1, 2006 to November 19,
014, 195,270 females received one or more doses of HPV vaccine.
hey received a total of 528,913 publicly and privately funded doses
f vaccine over the study period. Nearly all of the vaccine was  qHPV
99.2% of doses). The majority of women received three doses of
PV vaccine (82.4%), while a smaller proportion received only two
oses (9.9%) or only one dose (6.4%). Most were aged 9–14 years
79.5%) when their ﬁrst dose of HPV vaccine was received, followed
y age groups 15–19 years (10.0%), 20–24 years (5.9%), or 25–29
ears (2.7%).
able 1
istribution of HPV vaccine by numbers of women  aged 9+ years immunized, by
ttributes of recipients and vaccine.
Characteristic Number of women  (%)
N women  immunized 195,270 (100)
Number of doses received per individual
1 12,473 (6.4)
2 19,280 (9.9)
3 160,950 (82.4)
4+ 2567 (0.1)
Age (years) at which ﬁrst dose of vaccine received
9–14 155,300 (79.5)
15–19 19,483 (10.0)
20–24 11,551 (5.9)
25–29 5351 (2.7)
30–34 1725 (0.9)
35–39 874 (0.4)
40–44 583 (0.3)
45+ 403 (0.2)
Type of vaccine funding
Public 164,743 (84.4)
Private 29,025 (14.9)
Mixeda 1502 (0.8)
Total number of doses dispensed/administered 528,913 (100)
Type of vaccine dispensed/administered
qHPV 524,645 (99.2)
bHPV 4193 (0.8)
Unknown 75 (<0.1)
a Mixed funding: some doses were publicly funded, some were privately pur-
hased. (2016) 1800–1805
3.2. Frequency of occurrence of AEFI & serious AEFI events
Of the 195,270 women  who received HPV vaccine, 192 (<0.1%)
reported one or more AEFI events (198 AEFI events). Of the 192,
186 reported one AEFI event, while six reported two different AEFI
events. All AEFI events occurred after receipt of the qHPV vaccine.
Six persons who experienced an AEFI had received one or more
vaccines in addition to HPV on the same day as they received HPV
vaccine. Table 2 displays the frequency of occurrence of types of
AEFI by dose of HPV vaccine in series received that corresponded to
the AEFI event. Among the 198 events, the most commonly reported
events were allergic reaction (n = 90), other unusual events (n = 34),
other rash (n = 32), and pain and/or swelling (n = 23) (Table 2).
Most AEFI events occurred after receipt of the ﬁrst dose of vac-
cine (n = 117), followed by second (n = 55) and third (n = 25) doses.
Review of the text ﬁelds for ‘other unusual events’ found none of
these events to be consistent with VTE.
Of the 192 persons reporting AEFI events, ﬁve had a serious AEFI,
(all classiﬁed as ‘serious’ because of hospitalization); however only
4 of them were hospitalized within 42 days of immunization. The
ﬁfth person was  hospitalized on day 110, well outside of the 42 day
window.
3.3. Rate of occurrence & outcome of AEFI events
Over the study period, the rate of AEFI events was  37.4 per
100,000 doses of HPV vaccine administered (95% CI: 32.5–43.0). The
rate varied over time: no events were reported for 2006 or 2007,
however only about 5000 doses of vaccine were dispensed in those
years (data not shown). For the period January 1, 2008–November
19, 2014, the rate was 37.7 per 100,000 doses (95% CI: 32.8–43.3).
AEFI rates varied over time, peaking in 2011 (Fig. 1).
Of the 198 AEFI events, the outcomes were known for 171, all of
which were full recovery.
3.4. Hospitalization within 42 days of vaccination
Among the 195,270 females who received HPV vaccine, 958
were hospitalized (1053 hospitalization events) within 42 days of
immunization; however only 4 of those hospitalized had a reported
AEFI (see above). Of the 958 who were hospitalized, most (861,
89.8%) had only one hospitalization event within 42 days of immu-
nization. The large majority of those hospitalized were aged 9–14
years (66.0%) or 15–19 years (22.0%). The proportion of hospitaliza-
tions that occurred on the same day as vaccination was 0.7%, 34.6%
within 1–14 days, 32.8% within 15–28 days, and 31.9% within 29–42
days (data not shown).
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Table  2
Distribution of types of AEFI by dose of vaccine for which AEFI event reported.a
Number of doses of HPV vaccine received at time of occurrence of AEFI N persons
1 2 3 5
Allergic reaction 54 32 4 0 90
Other unusual events 20 10 4 0 34
Other rash 23 3 6 0 32
Pain  and/or swelling 12 5 5 1 23
Fever  1 2 1 0 4
Severe diarrhea 1 2 1 0 4
Anaphylaxis 2 0 1 0 3
Adenopathy 1 1 0 0 2
Convulsion/seizure 1 0 1 0 2
Anesthesia/paraesthesia 1 0 0 0 1
Arthralgia/arthritis 0 0 1 0 1
Erythema multiforme 0 0 1 0 1
Sterile abscess 1 0 0 0 1
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Table 3
Frequency of most responsible diagnoses among women hospitalized within 42 days
of  immunization.
ICD 10 Chapter codes Count (%)
Certain infectious and parasitic diseases (A00-B99) 29 (2.8)
Neoplasms (C00-D49) 22 (2.1)
Diseases of the blood and blood-forming organs
and certain disorders involving the immune
mechanism (D50-D89)
12 (1.1)
Endocrine, nutritional and metabolic diseases
(E00-E89)
35 (3.3)
Mental, Behavioral and Neurodevelopmental
disorders (F01-F99)
204 (19.4)
Diseases of the nervous system (G00-G99) 35 (3.3)
Diseases of the eye and adnexa (H00-H59) 4 (0.4)
Diseases of the ear and mastoid process (H60-H95) 8 (0.8)
Diseases of the circulatory system (I00-I99) 15 (1.4)
Diseases of the respiratory system (J00-J99) 104 (9.9)
Diseases of the digestive system (K00-K95) 165 (15.8)
Diseases of the skin and subcutaneous tissue
(L00-L99)
8 (0.8)
Diseases of the musculoskeletal system and
connective tissue (M00-M99)
73 (7.0)
Diseases of the genitourinary system (N00-N99) 54 (5.2)
Pregnancy, childbirth and the puerperium
(O00-O9A)
8 (0.8)
Certain conditions originating in the perinatal
period (P00-P96)
1 (0.1)
Congenital malformations, deformations and
chromosomal abnormalities (Q00-Q99)
19 (1.8)
Symptoms, signs and abnormal clinical and
laboratory ﬁndings, not elsewhere classiﬁed
(R00-R99)
66 (6.3)
Injury, poisoning and certain other consequences
of external causes (S00-T88)
144 (13.8)
External causes of morbidity (V00-Y99) 0 (0)
Factors inﬂuencing health status and contact with
health services (Z00-Z99)
41 (3.9)Total  117 55 
a Six of the 192 persons who experienced an AEFI had an AEFI on two occasions.
Thirty-two women had hospital transfers. Thirty-one women
ad one hospital transfer and one woman had two  transfers, result-
ng in 69 hospitalization events. Of these, six transfers (12 events)
ad the same most responsible diagnosis. Fourteen women  had
ultiple hospitalization records because they received two doses of
PV vaccine within 42 days, and thus both doses were temporally
ssociated with the hospitalization. Fifty-two persons had more
han one hospitalization event because they were hospitalized on
eparate occasions (i.e., these were not hospital transfers). From
he 1053 hospitalization events, after accounting for transfers, we
ounted 1047 most responsible diagnoses.
The frequencies of the 1047 most responsible diagnoses are
hown in Table 3. Mental, behavioral and neurodevelopmental dis-
rders (19.4%) were the most frequently coded most responsible
iagnoses, followed by diseases of the digestive system (15.8%),
nd injury, poisoning and certain other consequences of external
auses (13.8%).
.5. Identiﬁcation of VTE among those hospitalized
In addition to assessing frequencies of the most responsible
iagnoses we  examined all ICD-10-CA diagnostic codes (in any of
he ﬁelds possible for hospitalizations) for codes corresponding to
ur case deﬁnition of VTE. There were three women who had such
odes. The ﬁrst had a most responsible diagnosis of Z50.1 (other
hysical therapy), and an I80.2 other diagnosis. She was 26 years
f age and received the ﬁrst dose of HPV vaccine 23 days prior to
ospitalization. The other ICD-10-CA codes were consistent with
aving incurred an injury.
The second, aged 11 years, had a most responsible diagnosis of
07.4 (chest pain unspeciﬁed), and an I80.1 other diagnosis. She had
eceived the third dose of HPV vaccine 14 days prior to hospitaliza-
ion. The other ICD-10-CA codes for this hospitalization indicated
he presence of a congenital heart defect known to be associated
ith VTE.
The third was hospitalized for most responsible diagnosis of
80.2 (phlebitis and thrombophlebitis of other deep vessels of lower
xtremities). She was 14 years of age and received the third dose of
PV vaccine 11 days prior to hospitalization. Review of the other
CD 10 codes for this hospitalization indicated that the VTE was
lassiﬁed as a complication of other diagnoses (sepsis) that caused
he hospitalization.
Two of these three persons had received one or more vaccines
n addition to HPV on the same days as they received HPV vaccine.
one of those hospitalized with a VTE diagnosis died.Total 1047 (100)
3.6. ED visits within 42 days of immunization
Among those who received HPV vaccine, 19,351 had an ED visit
within 42 days of immunization (26,849 events). Of these, 713 also
had a hospitalization within 42 days. Among those with an ED visit
and hospitalization event, 4 were diagnosed with VTE (including
the 3 hospitalized with a VTE diagnosis described above). One per-
son visited the ED and was diagnosed with VTE, but did not have
any ICD-10-CA codes consistent with VTE among the discharge
diagnoses for the hospitalization.
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. Discussion
In this study, we linked vaccination data with AEFI reports, hos-
italization records, and ED visit records, at a population-level, to
escribe AEFI type as well as to identify VTEs that may  be related
o HPV vaccination among women aged 9 years or older. We  found
n AEFI rate (37.4/100,000 doses) that was substantially less than
hat from reports from the American Vaccine Adverse Event Repor-
ing System (VAERS) (53.9/100,000 doses) [14]. The most common
ypes of adverse events that we observed (e.g., allergic reactions,
other unusual events’, rash) were similar to those found from
nalysis of the VAERS data [14] and similar to those seen in the
rovince of Ontario [15]. Our results are consistent with other large
ost-licensure safety and surveillance studies that found that HPV
accines are safe [11,16].
While we observed three cases of VTE among those hospitalized
ithin 42 days of immunization, all three had other health condi-
ions known to be associated with VTE. While one additional person
ad an ED visit with a VTE code, this code was not among the dis-
harge diagnoses for the immediately following hospitalization. We
hink it likely that the VTE diagnosis from the ED visit was a tenta-
ive diagnosis that was not substantiated by further investigations
uring hospitalization. While Gee and colleagues [4] noted an asso-
iation with VTE after HPV immunization, this association was not
tatistically signiﬁcant, only ﬁve conﬁrmed cases were observed
nd all of those cases had other known risk factors for VTE. Other
nvestigators have found no association between HPV vaccination
nd the occurrence of VTE [11,16–18].
In Alberta, AEFI events are reportable if they meet case deﬁni-
ions outlined by Alberta Health [10]. AEFI reports are reviewed
y public health nurses who ensure AEFIs meet case deﬁnitions
nd enter the data into Imm/ARI. We  found a higher rate of AEFI
vents (37.4/100,000) than that reported for the Ontario schoolgirl
PV immunization program over 2007–2011 (19.2/100,000 doses
ispensed) [15]. These differences are almost certainly due to the
se of stricter guidelines for the classiﬁcation of AEFI in Ontario.
arris and colleagues identiﬁed 213 qHPV AEFI reports for Ontario,
f whom only the 133 classiﬁed as ‘conﬁrmed’ were used in their
nalyses. If all 213 reports had been used, the Ontario rate of AEFI
ould have been 30.7/100,000; a rate much closer to that which
e observed. However, as was also seen in Ontario, AEFI rates var-
ed by year. Passive surveillance data may  be affected by numerous
actors, including “biased reporting, underreporting and the inabil-
ty to determine whether a vaccine caused the adverse event in
ny individual report” [19]. Changes in reporting may  result from
hanges in the reporting practices of healthcare personnel, or by
ommunity concerns (resulting in increased reporting to health-
are personnel) [20,21]. It is possible that the 2011 publication of
he report of Gee and colleagues [4] might have affected reporting
ates elsewhere, including in Ontario and in Alberta. However it is
lso possible that a longer follow-up time for HPV immunizations
dministered in the earlier years of the study period may  also have
ontributed to the observed pattern of reporting.
The strengths of this study included capturing women who had
eceived either publicly funded or privately purchased HPV vac-
ines. Similarly, in addition to the passively reported AEFI data,
ur design overcame the limitations of passive reporting in our
earch for VTE by accessing the records of all hospitalizations for
he entire population of women immunized regardless of types
f vaccine received or modes of vaccine funding. However, our
tudy also has limitations. Residents of Alberta who were hospi-
alized within Alberta but immunized out of province would not
ave been captured. Similarly, those who were immunized within
lberta but hospitalized out of province would not have been cap-
ured. We do not know how many women this would be, but posit
hat the numbers are small. We  did not validate the ICD codes for
[ (2016) 1800–1805
hospitalizations or emergency department visits by chart review.
As the predictive value of ICD codes for VTE is variable [17] this
may  have led to misclassiﬁcation of outcome. Even in the absence
of misclassiﬁcation, it is possible that VTE identiﬁed during hospi-
talization might have had symptom onset prior to hospitalization.
Finally, the women  in our study received 528,913 doses of vaccine:
thus AEFI that occur very rarely but which are truly associated with
immunization with HPV vaccine would not be detected.
5. Conclusion
Adverse events following HPV immunization in Alberta are low,
consistent with those seen elsewhere, and consistent in the types
of event seen elsewhere.
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